Drugs and Devices

On Dec. 1, the U.S. Food and Drug Administration (FDA) approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). This is the first biosimilar approved . . .

A study in Nursing Research reports that automated pressure injury risk assessment system, which is built into an electronic health record and doesn’t require nurses to input additional data, was comparable to the Braden Scale.

Read more via journals.lww.com . . .

The U.S. Food and Drug Administration (FDA) has approved a medical device accessory for the Apple Watch that can detect arrhythmia and display on the face of the watch.

Read more via prnewswire.com . . .

On Nov. 21, the U.S. Food and Drug Administration (FDA) approved Juluca, the first treatment regimen containing two drugs to treat certain adults with HIV-1 instead of three or more drugs included in standard HIV treatment.

Read more via Fda.gov . . .

On Nov. 13, the U.S. Food and Drug Administration (FDA) approved Abilify MyCite, a pill with a sensor that digitally tracks if patients have ingested their medication. Read more via Fda.gov . . .

October 2017 Vol. 12 No. 10

Prolonged use of serotonin reuptake inhibitors (SRIs) in children and adolescents may increase the risk of developing type 2 diabetes, according to a study in JAMA Pediatrics.

Read more via Jamanetwork.com . . .

October 2017 Vol. 12 No. 10

On Oct. 13, the U.S. Food and Drug Administration (FDA) cleared the Senhance System, a new robotically-assisted surgical device (RASD) that can help facilitate minimally invasive surgery. Read more via Fda.gov . . .

On Sept. 28, the U.S. Food and Drug Administration (FDA) approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after endocrine therapy.Read more via FDA.gov . . .

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing